| Name | parathyroid hormone |
|---|---|
| Synonyms | PTH; Parathormone; Parathyrin; Parathyroid hormone; Parathyroid hormone precursor; Parathormones; Parathyrins; Parathyroid hormones… |
| Name | sodium fluoride |
|---|---|
| CAS | sodium fluoride (NaF) |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 16194044 | Okopien B, Krysiak R, Labuzek K, Herman ZS: [Anabolic therapy of osteoporosis] . Pol Merkur Lekarski. 2005 Jul;19(109):118-21. In the present study we describe in details sodium fluoride, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), growth hormone, insulin-like growth factor I, and parathormone and its analogues, describing their mechanism of action and adverse effects. |
81(1,1,1,1) | Details |
| 16124390 | Okopien B, Krysiak R, Labuzek K, Herman ZS: [Anabolic therapy in osteoporosis--part 1] . Pol Merkur Lekarski. 2005 Jun;18(108):712-4. In the present study we describe in details sodium fluoride, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), growth hormone, insulin-like growth factor I, and parathormone and its analogues, describing their mechanism of action and adverse effects. |
81(1,1,1,1) | Details |
| 9145241 | Sogaard CH, Mosekilde L, Thomsen JS, Richards A, McOsker JE: A comparison of the effects of two anabolic agents and PTH) on ash density and bone strength assessed in an osteopenic rat model. Calcif Tissue Int. 1997 Oct;61(4):272-8. The aim of this investigation was to compare the effects of sodium fluoride (NaF) and parathyroid hormone (PTH) on ash density and strength in an osteopenic rat model. |
6(0,0,1,1) | Details |
| 9673863 | Castelo-Branco C: Management of osteoporosis. Drugs Aging. 1998;12 Suppl 1:25-32. Other widely used treatments for osteoporosis that have been utilised to prevent bone loss include calcitonin and bisphosphonates, supplementation, ossein-hydroxyapatite compound, analogues, sodium fluoride, parathyroid hormone, anabolic steroids and growth hormone. |
6(0,0,1,1) | Details |
| 18360603 | Maclaughlin EJ, Sleeper RB, McNatty D, Raehl CL: Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag. 2006 Sep;2(3):281-95. Drugs which have been shown to decrease the risk of age-related osteoporotic fractures include oral bisphosphonates ibandronate, and risedronate), intranasal calcitonin, estrogen receptor stimulators (eg, selective estrogen receptor modulators [raloxifene]), parathyroid hormone (teriparatide), sodium fluoride, and ranelate. |
6(0,0,1,1) | Details |
| 15758502 | Jee WS: Anabolic agents and osteoporosis: quo vadis? . J Musculoskelet Neuronal Interact. 2000 Dec;1(2):107-11. There are preclinical studies and limited clinical experiences with bone and muscle anabolic agents (e.g., parathyroid hormone (PTH), sodium fluoride (NaF), prostaglandins (PGs), growth hormones (GH), etc.) that show they have significant advantages over antiremodeling agents in patients with established osteoporosis. |
6(0,0,1,1) | Details |
| 9312196 | Zerwekh JE, Padalino P, Pak CY: The effect of intermittent slow-release sodium fluoride and continuous therapy on calcitropic hormones, biochemical markers of bone metabolism, and blood chemistry in postmenopausal osteoporosis. Biol Pharm Bull. 2000 May;23(5):581-4. After 2 years of therapy, a significant reduction in serum immunoreactive parathyroid hormone (PTH) was seen for both groups (43 +/- 18 SD-30 +/- 11 ng/liter, in placebo and 46 +/- 24-36 +/- 10, in SRNaF P < 0.0001 for both groups). |
1(0,0,0,1) | Details |
| 12854284 | Romagnoli E, Paglia F, Dionisi S, De Geronimo S, Pepe J, Di Virgilio R, Minisola S: [Male osteoporosis: current treatments and future options] . Clin Ter. 2003 Jan-Feb;154(1):49-53. As far as anabolic treatments are concerned, there is not agreement on clinical utility of sodium fluoride. Short-term treatment with parathyroid hormone (PTH) seems to be safe and effective in patients with idiopathic osteoporosis, due to its anabolic action. |
1(0,0,0,1) | Details |
| 15911210 | Simon LS: Osteoporosis. . Clin Geriatr Med. 2005 Aug;21(3):603-29 Newer therapies such as parathyroid hormone may improve the fracture risk even more than biphosphonates over a shorter period of time. |
1(0,0,0,1) | Details |
| 9881322 | Netelenbos C: Osteoporosis: intervention options. Maturitas. 1998 Nov 16;30(3):235-9. On the other hand bone formation stimulating agents as fluorides and in the near future parathyroid hormone and analogues must be considered also. At this moment sodium fluoride is not the first choice in treatment of osteoporosis in general practice. |
1(0,0,0,1) | Details |
| 17220054 | Di Loreto V, Rigalli A, Puche R: Effect of sodium fluoride administration to rats on bone content and phosphatemia. Arzneimittelforschung. 2006;56(11):760-6. |
0(0,0,0,0) | Details |
| 10677797 | Blank RD, Bockman RS: A review of clinical trials of therapies for osteoporosis using fracture as an end point. Bone. 1997 May;20(5):439-49. Fracture outcomes have been reported in clinical trials with supplementation, supplementation, replacement therapy (ERT), calcitonin, etidronate, (NaF), parathyroid hormone (PTH), and raloxifene. |
1(0,0,0,1) | Details |
| 10823668 | Murao H, Sakagami N, Iguchi T, Murakami T, Suketa Y: Sodium fluoride increases intracellular in rat renal epithelial cell line NRK-52E. Am J Physiol. 1997 Sep;273(3 Pt 1):E528-35. In our previous experiment using rats, was reported to cause renal calcification, whose mechanism was deduced to be due to an increase in parathyroid hormone (PTH) secretion. |
1(0,0,0,1) | Details |
| 9578891 | Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston S, Reeve J, Reid DM, Russell RG, Stevenson JC: Management of male osteoporosis: report of the UK Consensus Group. QJM. 1998 Feb;91(2):71-92. Bisphosphonates are the treatment of choice in idiopathic osteoporosis, with sodium fluoride and anabolic steroids to be used as alternatives. Age-related bone loss may be a result of declining renal function, deficiency, increased parathyroid hormone levels, low serum levels, low intake and absorption. |
1(0,0,0,1) | Details |
| 9316442 | Mitchell J, Bansal A: Dexamethasone increases G alpha q-11 expression and hormone-stimulated phospholipase C activity in UMR-106-01 cells. viii. We examined the effect of glucocorticoids on parathyroid hormone (PTH) activation of two G protein-activated signal transduction pathways, phospholipase C (PLC) and adenylyl cyclase, in osteosarcoma UMR-106-01 cells. |
1(0,0,0,1) | Details |